Skip to Content
Merck
All Photos(1)

Documents

T2815

Sigma-Aldrich

Transforming Growth Factor-β2 human

≥97% (electrophoresis), recombinant, expressed in NSO cells, powder, suitable for cell culture

Synonym(s):

hTGF-β2, TGF-β2

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352202
NACRES:
NA.77

product name

Transforming Growth Factor-β2 human, TGF-β2, recombinant, expressed in NSO cells, powder, suitable for cell culture

biological source

human

Quality Level

recombinant

expressed in NSO cells

Assay

≥97% (electrophoresis)

form

powder

potency

0.04 ng/mL ED50

quality

endotoxin tested

mol wt

25 kDa

packaging

pkg of 10 μg
pkg of 2 μg

storage condition

avoid repeated freeze/thaw cycles

technique(s)

cell culture | mammalian: suitable

impurities

≤1 EU/μg

suitability

suitable for

UniProt accession no.

storage temp.

−20°C

Gene Information

Looking for similar products? Visit Product Comparison Guide

General description

The transforming growth factor-β2 (TGFB2) gene is mapped to human chromosome 1q41. The encoded protein is localized to extracellular matrix. TGF-β2 is a member of the TGF-β superfamily. TGF-β exists in three isoforms (TGF-β1, TGF-β2 and TGF-β3) and are known to share similar structure and function.

Application

Transforming Growth Factor-β2 human has been used in chondrogenic, adipogenic and osteogenic differentiation of mesenchymal stem cells. It has also been used to induce extracellular matrix accumulation in primary human trabecular meshwork cells and further to study the action of tetramethylpyrazine on the same.

Biochem/physiol Actions

TGF-β2 is known to stimulate cell growth, differentiation, migration and survival. TGF-β2 acts as a key regulator for immune homeostasis by controlling lymphocyte proliferation, embryogenesis, hematopoiesis and apoptosis. TGF-β is also associated with inflammation and wound healing and is considered as a strong growth inhibitor for keratinocyte cells. TGF-β is associated with the process of tumor development, progression and metastasis. TGF-β2 is a tumor suppressor in the early stages of carcinogenesis, but in the later stages acts as a tumor promoter by inducing epithelial-mesenchymal transition and stimulating angiogenesis. The TGF-β gene is overexpressed in glioma tumors and also in colon cancer, gastric cancer and cervical lesions.
Transforming growth factor-β2 (TGF-β2), like TGF-β1, is produced by many cell types and reported to be most concentrated in mammalian platelets.

Physical form

Lyophilized from a 0.2 μm filtered solution in 30% acetonitrile and 0.1% trifluoroacetic acid containing 0.1 mg bovine serum albumin

Analysis Note

The biological activity is measured by its ability to inhibit the IL-4-dependent proliferation of mouse HT-2 cells.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A signaling pathway involving TGF-β2 and snail in hair follicle morphogenesis.
Jamora C, et al.
PLoS Biology, 3.1 (2004)
Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm
Lindsay ME, et al.
Nature Genetics, 44(8), 922?927-922?927 (201)
Evaluation of zinc finger E-box binding homeobox 1 and transforming growth factor-β2 expression in bladder cancer tissue in comparison with healthy adjacent tissue
Mahdavinezhad A, et al.
Investigative and Clinical Urology, 58(2), 140?145-140?145 (2017)
Preliminary Results of Tissue-Engineered Injection Laryngoplasty
Material in a Rabbit Model
Oldenburg MS, et al.
Laryngoscope, 128, 160-167 (2018)
Michael S Oldenburg et al.
The Laryngoscope, 128(1), 160-167 (2017-09-13)
Design and test a novel biomaterial for injection laryngoplasty aimed to increase the duration of effectiveness of micronized acellular dermis. Animal model. Injection laryngoplasty was performed in three groups (n = 5) of New Zealand White rabbits. Acellular dermis was

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service